🇺🇸 rHuEPO in United States

9 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 9

Most-reported reactions

1. Bronchiectasis — 1 report (11.11%)
2. Bronchitis — 1 report (11.11%)
3. Epistaxis — 1 report (11.11%)
4. Haematocrit Decreased — 1 report (11.11%)
5. Haemoglobin Decreased — 1 report (11.11%)
6. Leukopenia — 1 report (11.11%)
7. Nasopharyngitis — 1 report (11.11%)
8. Thrombocytopenia — 1 report (11.11%)
9. Upper Respiratory Tract Infection — 1 report (11.11%)

Source database →

Frequently asked questions

Is rHuEPO approved in United States?

rHuEPO does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for rHuEPO in United States?

Amgen is the originator. The local marketing authorisation holder may differ — check the official source linked above.